Sign in
4

Changes in Ownership

Aligos Therapeutics, Inc. Filed Acc 0001610717-23-000319

Chief Executive Officer acquired 610,277 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

BLATT LAWRENCE · Chief Executive Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-10-25 Grant or award : show line 1 in the form +610,277 $0.76 $461,858 1,847,575 D

Table II: Derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-10-25 Grant or award : show line 2 in the form Warrants (Right to Buy) +305,138 $0.13 $38,142 305,138 D
Loading xslF345X05/form4.xml…